In addition, participants with NAFLD had significantly higher levels of liver enzymes (AST, ALT, alkaline phosphatase, GGT), inflammatory biomarkers (ferritin, hs-CRP), glycemic markers (glucose, HbA1c, HOMA-IR), and lipoproteins (cholesterol, triglycerides, LDL-C), but lower HDL-C values than those without NAFLD. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.